SCHEMBL3882837

SCHEMBL3882837

O=C(c1cc[nH]n1)N1CCC(c2nc3c(s2)CCN(C2CCC2)CC3)CC1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 8/20 0.37
L3MBTL1 Q9Y468 7/20 0.37
HRH3 Q9Y5N1 5/20 0.36
CYP2D6 P10635 1/20 0.36
MBTD1 Q05BQ5 1/20 0.34
TP53BP1 Q12888 1/20 0.34
L3MBTL4 Q8NA19 1/20 0.34
UBE2M P61081 6/20 0.34
DCUN1D1 Q96GG9 6/20 0.34
LMNA P02545 2/20 0.34
TP53 P04637 2/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3882841 0.83 UBE2M (0.33) UBE2MDCUN1D1LMNATP53POLB
SCHEMBL3879769 0.83 L3MBTL1 (0.45) L3MBTL3L3MBTL1HRH3CYP2D6UBE2M
SCHEMBL3879089 0.82 KDM4E (0.51) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL3878875 0.82 SMN1; SMN2 (0.39) L3MBTL3L3MBTL1HRH3CYP2D6UBE2M
SCHEMBL3878386 0.82 HRH3 (0.38) L3MBTL3L3MBTL1HRH3CYP2D6UBE2M
SCHEMBL3877921 0.82 GRM5 (0.46) L3MBTL3L3MBTL1HRH3CYP2D6UBE2M
SCHEMBL3882219 0.82 ALDH1A1 (0.40) L3MBTL3L3MBTL1CYP2D6ALDH1A1TSHR
SCHEMBL3883408 0.81 KDM5A (0.37) L3MBTL3L3MBTL1HRH3CYP2D6UBE2M
SCHEMBL3878900 0.81 HRH3 (0.37) L3MBTL3L3MBTL1HRH3CYP2D6UBE2M
SCHEMBL3885754 0.81 POLB (0.41) L3MBTL3L3MBTL1HRH3CYP2D6UBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP claimed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US claimed
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH2 L3MBTL3 2880/4885L3MBTL1 2435/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.